Starpharma Holdings Limited · ASX:SPL
Starpharma — Australian Microcap Investment Conference 2024
30 slides from Starpharma's conference presentation, Oct 29, 2024
Slide 1: ASX Announcement: Australian Microcap Conference Presentation
ASX Announcement Australian Microcap Conference Presentation Melbourne, Australia; 29 October 2024: Starpharma (ASX: SPL, OTCQX: SPHRY), an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient, provides a copy of the presentati
Slide 2: Delivering Meaningful Patient Outcomes with Advanced Dendrimer Technology
For personal use only ASX : SPL OTCQX : SPHRY Delivering Meaningful Patient Outcomes with Advanced Dendrimer Technology Microcap Investment Conference | 29 October 2024 CEO, Cheryl Maley
Slide 3: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements For personal use only This presentation contains forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, Starpharma can give no assura
Slide 4: Our Mission
For personal use only “To help patients with significant illnesses, such as cancer, achieve Our Mission improved health outcomes and quality of life through the application of our unique dendrimer technology.” 3
Slide 5: Starpharma is an Innovative Australian Biotechnology Company
Starpharma is an Innovative Australian Biotechnology Company with 20 Years of Experience in Advancing Dendrimer Technology from the Lab to the Patient For personal use only ASX: SPL Ticker Symbol OTCQX: SPHRY Healthcare, Industry/Sector Pharmaceuticals, Biotechnology Market ~A$40M Capitalisation Sha
Slide 6: Starpharma – Founders and Experts in Dendrimer Drug Delivery
Starpharma – Founders and Experts in Dendrimer Drug Delivery For personal use only Dendrimers are highly branched (tree-like) macromolecules with a well-defined, 3D structure Clinically validated technology Dendrimer Generations More than 350 patients treated with DEP® across multiple clinical progr
Slide 7: Proprietary DEP Technology Has the Potential to Address Limitations
Starpharma’s Proprietary DEP® Technology Has the Potential to Address Limitations of a Wide Range of Diagnostics and Therapies For personal use only DEP® Nano molecule The Problem The Solution Despite advancements in medical By applying Starpharma's DEP® diagnosis and treatment, many Drug/Payload (e
Slide 8: DEP Platform Technology: Versatile and Multifunctional
Starpharma’s DEP® Platform Technology: Versatile and Multifunctional for Delivery of Therapeutics and Diagnostics Multiple Revenue Streams: Maximising Shareholder Returns For personal use only DEP® SN38 and DEP® cabazitaxel: Phase II commercial opportunities to address Clinical unmet needs in oncolo
Slide 9: Recent Strategic Review Confirmed Three Key Focus Areas
Recent Strategic Review Confirmed Three Key Focus Areas to Optimise Shareholder Returns For personal use only 01 02 03 Maximise DEP® Accelerate early Build long-term asset value asset sustainability development Increasing revenue, Prioritising DEP® SN38 and DEP® Advancing DEP® strengthening IP posit
Slide 10: Maximise DEP Asset Value
Phase II Clinical Assets For personal use only Rapidly Maximise DEP ® Strategic Emerging Partnerships Therapies DEP Asset Value Platform OTC Future Products on Opportunities Market 9
Slide 11: Starpharma's Oncology Portfolio: Addressing Areas of High Unmet Clinical Need
Starpharma’s Oncology Portfolio: Addressing Areas of High Unmet Clinical Need Three Clinical Assets and Three Pipeline Assets For personal use only Target Product Research Preclinical Phase I Phase II Strategy indication Ovarian and DEP® SN38 Phase II results reported License/co-develop – ovarian, c
Slide 12: Every Moment Matters When Advanced Cancers Lead to Increased Mortality Risks
Every Moment Matters When Advanced Cancers Lead to Increased Mortality Risks For personal use only Colorectal Cancer (colon cancer or bowel cancer) • 3rd most common cancer worldwide and 2nd leading cause of cancer-related deaths worldwide. • Often diagnosed at advanced stages when treatment options
Slide 13: DEP SN38: Lead Clinical Candidate for Colorectal and Ovarian Cancer
DEP® SN38: Starpharma’s Lead Clinical Candidate for Treatment of Advanced Colorectal Cancer and Platinum- Resistant/Refractory Ovarian Cancer For personal use only DEP® SN38 is a patented anticancer drug developed by Starpharma. It contains ‘SN38’, the active metabolite of irinotecan, a well-known c
Slide 14: DEP SN38 Phase I/II Trial Patients
DEP® SN38 Phase I/II Trial Patients – Advanced, Heavily Pre-treated, and Most CRC Patients had Progressed Following Prior Treatment with Irinotecan For personal use only BASELINE CHARACTERISTICS COLORECTAL OVARIAN PANCREATIC BREAST OTHER1 TOTAL Subjects enrolled (n, %) 55 (48%) 23 (20%) 15 (13%) 8 (
Slide 15: DEP SN38 Phase II Study Shows Favourable Efficacy Data
DEP® SN38 Phase II Study Shows Favourable Efficacy Data in Late-Stage Patients Results Presented at the 2024 ASCO Annual Meeting For personal use only Advanced Colorectal Cancer Advanced Platinum-Resistant Ovarian Cancer 4.5 4.2 16 12 50 14 10.4 45 43 4 14 10 3.5 40 12 2.8 35 3 8 10 30 2.5 8 6 25 2
Slide 16: DEP SN38 Well-tolerated with Mostly Mild/Moderate GI AEs
DEP® SN38 Well-tolerated with Mostly Mild/Moderate Gastrointestinal AEs, No Cholinergic Toxicity Results Presented at the 2024 ASCO Annual Meeting For personal use only Gastrointestinal Toxicity Profile Significantly Improved with DEP® SN38 Treatment, Compared to Published Data on Irinotecan* 50% 47
Slide 17: DEP Technology Designed to Improve Patient Outcomes
Starpharma’s DEP® Technology is Designed to Improve Patient Outcomes with Enhanced Drug Performance: Better Efficacy and Reduced Side Effects For personal use only Key Benefits of Starpharma’s DEP® Technology Demonstrated in Ph II Clinical Studies Improved Treatment Effectiveness with Better Drug Ta
Slide 18: Accelerate Early Asset Development
Phase II Clinical Assets For personal use only Rapidly Strategic Accelerate Early Emerging Partnerships Therapies DEP Asset Development Platform Novel Areas OTC of Unmet Products on Need Market 17
Slide 19: Starpharma's Oncology Portfolio: Addressing Areas of High Unmet Clinical Need
Starpharma’s Oncology Portfolio: Addressing Areas of High Unmet Clinical Need Three Clinical Assets and Three Pipeline Assets For personal use only Target Product Research Preclinical Phase I Phase II Strategy indication Ovarian and DEP® SN38 Phase II results reported License/co-develop – ovarian, c
Slide 20: Benefits of DEP Platform Technology Extend to Radiopharmaceuticals
Benefits of Starpharma’s DEP® Platform Technology Extend to Radiopharmaceuticals For personal use only Ability to use a wide range of targeting moieties Site-specific attachment of dendrimer on targeting moiety DEP® dendrimers are precisely manufactured and easily scalable Drug-linker strategy flexi
Slide 21: Addressing Biodistribution Challenges with DEP Radiotheranostics
Addressing the Biodistribution Challenges of Current Approaches with DEP® Radiotheranostics For personal use only Biodistribution Challenges with Starpharma’s DEP® Technology Current Approaches: Solution: Rapid kidney clearance can lead to low tumour uptake DEP® is designed for optimal biodistributi
Slide 22: DEP HER2 Radiodiagnostic Shows Promise with Excellent Imaging Contrast
DEP® HER2 Radiodiagnostic Shows Promise with Excellent Imaging Contrast Between Tumour and Normal Tissue For personal use only DEP® HER2 radiodiagnostic: faster clearance from blood and sustained elevated tumour:blood ratios compared to trastuzumab-89Zr 12 50 % injected dose / gram of blood 45 DEP H
Slide 23: Significant Commercial Activity in Novel Areas Continues
Significant Commercial Activity in Novel Areas Continues Radiopharmaceuticals Have Seen Over $12 Billion in Deals During 2023-24 For personal use only Significant corporate deals in radiotheranostics US$1B US$2.5B US$1.4B US$1B May 2024 Mar 2024 Oct 2023 Sept 2023 ~US$2B €520M US$2.1B US$3.9B Nov 20
Slide 24: Accelerate Early Asset Development: Partnerships
Phase II Clinical Assets For personal use only Rapidly Strategic Accelerate Early Emerging Partnerships Therapies DEP Asset Development Platform Novel Areas OTC of Unmet Products on Need Market 23
Slide 25: Extensive Partnership Experience and Flexible Approach to Collaboration
Extensive Partnership Experience, Broad DEP® Application Opportunity and a Flexible Approach to Collaboration For personal use only R&D collaboration Types of Partnerships Co-development Applicable to a Wide and Collaboration Range of Therapeutic Opportunities Licence Areas Technology access Partner
Slide 26: Build Long-term Sustainability
Phase II Clinical Assets For personal use only Rapidly Strategic Build Long-term Emerging Partnerships Therapies DEP Sustainability Platform Novel Areas OTC of Unmet Products on Need Market 25
Slide 27: Novel Products In Market Generating Revenue: VivaGel BV and Viraleze
Novel Products In Market Generating Revenue: VivaGel® BV and Viraleze Nasal Spray For personal use only VivaGel® BV – a non-antibiotic topical gel Viraleze - a topical antiviral barrier nasal for the treatment of bacterial vaginosis (BV) spray for colds and respiratory viruses, and prevention of rec
Slide 28: Well Positioned to Accelerate Product Pipeline and Strategic Growth
Well Positioned to Accelerate Product Pipeline and Strategic Growth Initiatives For personal use only 3-Year Summary FY24 FY23 FY22 Multiple Revenue Streams $M $M $M • Licenses and Milestone Payments Revenue and other income 9.8 4.3 5.2 • Marketed Products: VivaGel® BV Loss for the period (8.2) (15.
Slide 29: Starpharma Investment Highlights Clear Strategic Priorities
Starpharma Investment Highlights 3 Clear Strategic Priorities For personal use only 1) Maximising DEP® asset value, 2) Accelerating early asset development, and 3) Building long-term sustainability Over 20 years of 3 Phase II Clinical Assets experience in advancing dendrimer Phase II results reporte
Slide 30: Thank you.
For personal use only ASX : SPL OTCQX : SPHRY Thank you. Investor Relations Corporate Office Investor.Relations@Starpharma.com 4 – 6 Southampton Crescent www.starpharma.com Abbotsford, Victoria 3067 Australia
Starpharma Holdings — Australian Microcap Investment Conference 2024 on 6ix